Lacosamidă Fresenius Kabi

Lacosamide, the active ingredient in Lacosamidă Fresenius Kabi, is an anticonvulsant presented as an intravenous formulation for intravenous use. It treats partial‑onset seizures as adjunctive therapy in patients with epilepsy.

GNH USA supplies Lacosamidă Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lacosamide is an anticonvulsant used to manage seizure disorders, particularly focal epilepsy.

Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic regimens. Adjunctive therapy for epilepsy: improves overall seizure control in patients with refractory epilepsy. Focal epilepsy: provides an additional mechanism of action to complement other antiepileptic drugs.

Lacosamide may cause a range of adverse reactions, from mild to severe. Awareness of these effects helps clinicians monitor patients appropriately.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Fatigue: feeling unusually tired. - Diplopia: double vision. - Blurred vision: reduced visual clarity.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR interval prolongation or arrhythmia. - Suicidal ideation: thoughts of self‑harm. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, angioedema, or anaphylaxis. - Respiratory depression: reduced breathing effort. - Hepatotoxicity: elevated liver enzymes or liver injury.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Renal impairment: adjust monitoring and consider dose modification. Hepatic impairment: use with caution and monitor liver function. Cardiac conduction disorders: obtain baseline ECG and monitor for PR interval changes. Pregnancy: risk unknown; prescribe only if benefit outweighs potential fetal risk. Drug interactions: review concomitant medications for possible interactions. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with several medications, influencing its plasma levels or cardiac effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide concentrations. - Drugs that prolong PR interval (e.g., class IA antiarrhythmics): heightened risk of cardiac conduction delay. - Concurrent sodium‑channel blockers (e.g., carbamazepine, phenytoin): may amplify adverse neurologic effects.

Moderate Interactions (Monitor Closely): - Carbamazepine (enzyme inducer): may reduce lacosamide levels. - Phenytoin (enzyme inducer): may lower lacosamide exposure. - Cimetidine (CYP2C19 inhibitor): may modestly raise lacosamide concentrations.